While companies fear losing to competitors, a bigger deterrent for head-to-head trials is the absence of a clear regulatory pathway to use favorable data (e.g., faster onset) for label claims. This removes a key commercial incentive for running these informative but risky studies.

A growing movement, particularly in the US, legally allows patients with terminal diseases to try unapproved therapies. This framework gives patients who have exhausted all other options the right to take a knowing risk on a potentially life-saving treatment.

The Huntington's community isn't demanding carte blanche approval for uniQure's drug. They are advocating for an accelerated pathway that grants access to patients who understand the risks, allowing for continued data collection without a five-year sham trial that could make them ineligible for treatment later.

The FDA's refusal to approve a promising Huntington's drug, despite strong biological evidence, has a chilling effect on the entire biotech ecosystem. Other drug companies become nervous, and venture capital funding for neurological and rare disease research is likely to retract without a clear path to market.

The FDA initially agreed uniQure could use the robust Enroll HD database for its control group, a standard practice for rare diseases. Their later reversal, demanding a new placebo trial, creates significant regulatory uncertainty, making it harder for companies to develop therapies for rare conditions.

The current unpredictability at the FDA is so pronounced that prominent biotech investor Peter Kolchinsky of RA Capital is now advising his portfolio companies to de-risk development by conducting early-stage clinical trials outside the United States. This marks a significant strategic shift for US-based innovators.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

Individual biotech executives are reluctant to publicly challenge the FDA because their companies have drugs under active review. Forming a broad coalition with investors and patient advocates allows them to voice concerns collectively, providing a shield against potential regulatory blowback that any single company might face if it spoke out alone.

Unlike other right-to-try laws, Montana's new program allows biotech companies to generate a profit from selling experimental drugs before they receive full FDA approval. This creates a powerful new economic incentive and potential funding lifeline for smaller drug developers, changing the risk-reward calculation for bringing new therapies to market.